Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | NMT2 | O60551 | 4/20 | 0.44 |
| ▸ | NMT1 | P30419 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11058465 | 0.86 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 | |
| SCHEMBL3618501 | 0.86 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 | |
| SCHEMBL3622124 | 0.85 | RAB9A (0.57) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 | |
| SCHEMBL3617991 | 0.84 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 | |
| SCHEMBL3614948 | 0.83 | RAB9A (0.62) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 | |
| SCHEMBL3613925 | 0.83 | EDNRA (0.56) | RAB9ASMN1; SMN2NPC1L3MBTL1KDM4E | |
| SCHEMBL3609779 | 0.80 | L3MBTL1 (0.48) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 | |
| SCHEMBL2909528 | 0.78 | L3MBTL1 (0.59) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 | |
| SCHEMBL3607399 | 0.75 | KDM4E (0.76) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 | |
| SCHEMBL10460783 | 0.75 | L3MBTL1 (0.61) | RAB9ASMN1; SMN2NPC1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | RAB9A 3864/4885SMN1; SMN2 3220/4885NPC1 2605/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | RAB9A 3864/4885SMN1; SMN2 3220/4885NPC1 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.